Viatris Inc. (VIA.DE)
- Previous Close
10.66 - Open
10.63 - Bid 10.72 x --
- Ask 10.84 x --
- Day's Range
10.63 - 10.63 - 52 Week Range
8.16 - 12.60 - Volume
50 - Avg. Volume
3,447 - Market Cap (intraday)
12.696B - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
212.60 - EPS (TTM)
0.05 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield 0.44 (4.14%)
- Ex-Dividend Date Mar 8, 2024
- 1y Target Est
--
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
www.viatris.com38,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: VIA.DE
Performance Overview: VIA.DE
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIA.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIA.DE
Valuation Measures
Market Cap
12.73B
Enterprise Value
28.80B
Trailing P/E
228.10
Forward P/E
4.13
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.89
Price/Book (mrq)
0.66
Enterprise Value/Revenue
1.87
Enterprise Value/EBITDA
8.19
Financial Highlights
Profitability and Income Statement
Profit Margin
0.35%
Return on Assets (ttm)
2.79%
Return on Equity (ttm)
0.26%
Revenue (ttm)
15.43B
Net Income Avi to Common (ttm)
54.7M
Diluted EPS (ttm)
0.05
Balance Sheet and Cash Flow
Total Cash (mrq)
1.18B
Total Debt/Equity (mrq)
89.76%
Levered Free Cash Flow (ttm)
1.1B
Company Insights: VIA.DE
VIA.DE does not have Company Insights